argenx SE

argenx SE a biotechnology company engages in the developing of various therapies for the treatment of autoimmune diseases in the United States the Netherlands Belgium Japan Switzerland Germany France Canada the United Kingdom and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis immune thrombocytopenia pemphigus vulgaris pemphigus foliaceus chronic inflammatory demyelinating polyneuropathy bullous pemphigoid and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119 an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114 an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L. Zai Lab Limited and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd Université Catholique de Louvain Sopartec S.A. NYU Langone Health Leiden University Medical Center AgomAb Therapeutics NV Broteio Pharma B.V. VIB vzw University of Texas BioWa Inc. Staten Biotechnology B.V. and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover develop and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam the Netherlands.